Zhejiang Huahai Pharmaceutical Secures Clinical Trial Approval for Asthma Treatment

MT Newswires Live

2024/11/01

Zhejiang Huahai Pharmaceutical (SHA:600521) subsidiary Shanghai Huaotai Biopharmaceutical secured approval to conduct clinical trials for its HB0056 injection in New Zealand.

The approval was obtained from the New Zealand Medicines and Medical Devices Safety Authority and the Health and Disability Ethics Committee, according to a Thursday filing with the Shanghai bourse.

HB0056 is indicated for the treatment of asthma.

Zhejiang Huahai Pharmaceutical shares rose 2% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2480044776"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480044776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2480044776?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 12:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480044776","market":"hk","top_or_hot":-1,"title":"Zhejiang Huahai Pharmaceutical Secures Clinical Trial Approval for Asthma Treatment","media":"MT Newswires Live","content":"<html><body><p> Zhejiang Huahai Pharmaceutical (SHA:600521) subsidiary Shanghai Huaotai Biopharmaceutical secured approval to conduct clinical trials for its HB0056 injection in New Zealand.</p><p>The approval was obtained from the New Zealand Medicines and Medical Devices Safety Authority and the Health and Disability Ethics Committee, according to a Thursday filing with the Shanghai bourse.</p><p>HB0056 is indicated for the treatment of asthma.</p><p>Zhejiang Huahai Pharmaceutical shares rose 2% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Huahai Pharmaceutical Secures Clinical Trial Approval for Asthma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Huahai Pharmaceutical Secures Clinical Trial Approval for Asthma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-01 12:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhejiang Huahai Pharmaceutical (SHA:600521) subsidiary Shanghai Huaotai Biopharmaceutical secured approval to conduct clinical trials for its HB0056 injection in New Zealand.</p><p>The approval was obtained from the New Zealand Medicines and Medical Devices Safety Authority and the Health and Disability Ethics Committee, according to a Thursday filing with the Shanghai bourse.</p><p>HB0056 is indicated for the treatment of asthma.</p><p>Zhejiang Huahai Pharmaceutical shares rose 2% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2480044776","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480044776","pubTimestamp":1730434965,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhejiang Huahai Pharmaceutical  subsidiary Shanghai Huaotai Biopharmaceutical secured approval to conduct clinical trials for its HB0056 injection in New Zealand.The approval was obtained from the New Zealand Medicines and Medical Devices Safety Authority and the Health and Disability Ethics Committee, according to a Thursday filing with the Shanghai bourse.HB0056 is indicated for the treatment of asthma.Zhejiang Huahai Pharmaceutical shares rose 2% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600521":"华海药业","BK0012":"证金概念","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","BK0201":"可转债","BK0188":"融资融券","BK0070":"员工持股"},"translate_title":"浙江华海药业获哮喘治疗临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":0.9},"content_text":"Zhejiang Huahai Pharmaceutical (SHA:600521) subsidiary Shanghai Huaotai Biopharmaceutical secured approval to conduct clinical trials for its HB0056 injection in New Zealand.The approval was obtained from the New Zealand Medicines and Medical Devices Safety Authority and the Health and Disability Ethics Committee, according to a Thursday filing with the Shanghai bourse.HB0056 is indicated for the treatment of asthma.Zhejiang Huahai Pharmaceutical shares rose 2% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}